Clinical studies have demonstrated that GLP-1RAs can effectively control blood glucose, induce weight loss, protect pancreatic β-cells, decrease visceral and hepatic fat deposits, and improve overall and hepatic insulin sensitivity in obese patients with T2DM and prediabetes [13, 14]. This evidence concerns the gene INS and prediabetes syndrome.